| Full text | |
| Author(s): |
Nunez-Rios, J. D.
;
Ulrich, H.
;
Diaz-Munoz, M.
;
Lameu, C.
;
Vazquez-Cuevas, F. G.
Total Authors: 5
|
| Document type: | Journal article |
| Source: | PURINERGIC SIGNALLING; v. N/A, p. 16-pg., 2023-11-15. |
| Abstract | |
Accumulating evidence supports the idea that cancer stem cells (CSCs) are those with the capacity to initiate tumors, generate phenotypical diversity, sustain growth, confer drug resistance, and orchestrate the spread of tumor cells. It is still controversial whether CSCs originate from normal stem cells residing in the tissue or cancer cells from the tumor bulk that have dedifferentiated to acquire stem-like characteristics. Although CSCs have been pointed out as key drivers in cancer, knowledge regarding their physiology is still blurry; thus, research focusing on CSCs is essential to designing novel and more effective therapeutics. The purinergic system has emerged as an important autocrine-paracrine messenger system with a prominent role at multiple levels of the tumor microenvironment, where it regulates cellular aspects of the tumors themselves and the stromal and immune systems. Recent findings have shown that purinergic signaling also participates in regulating the CSC phenotype. Here, we discuss updated information regarding CSCs in the purinergic system and present evidence supporting the idea that elements of the purinergic system expressed by this subpopulation of the tumor represent attractive pharmacological targets for proposing innovative anti-cancer therapies. (AU) | |
| FAPESP's process: | 22/11093-9 - Purinergic signaling in the phenotypic transition of Tumor Associated Macrophages (TAMs) and Circulating Tumor Cells (CTCs) to Breast Cancer brain metastasis |
| Grantee: | Claudiana Lameu |
| Support Opportunities: | Regular Research Grants |